The combined use of cytosine arabinoside, cyclophosphamide, and total body irradiation as preparative regimen for bone marrow transplantation in patients with AML and CML.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage*; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D007239:Infections / Q000209:etiology; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011658:Pulmonary Fibrosis / Q000209:etiology; D014916:Whole-Body Irradiation / Q000009:adverse effects
D003561:Cytarabine; D003520:Cyclophosphamide